Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to provide written informed consent.~* Male and aged 18 years and over.~* Diagnosed with PE according to DMS-IV criteria and ISSM definition~* Diagnosed with lifelong PE~* Acceptable response to Baseline PEP~* Subject must be in a stable heterosexual and monogamous relationship and the partner must provide consent~* Acceptable sexual encounters in the Baseline period.~Exclusion Criteria:~* Subject, or his sexual partner, has received an investigational (non-registered) drug within 30 days of Screening.~* Subject has erectile dysfunction~* The subject, or his sexual partner, has a physical or psychological condition that would prevent them from undertaking the study procedures, including, but not limited to, the following:~  * Urological disease~ * Ongoing significant psychiatric disorder not controlled by medication.~* Subject has safety testing abnormalities at the Screening Visit~* Subjects taking excluded medications or receiving any treatment for PE~* Subject, or his sexual partner, has a current history of alcohol or drug abuse,~* The subject, or his sexual partner, is unlikely to understand or be able to comply with study procedures, for whatever reasons.~* Subject, or his sexual partner, has known drug sensitivity to amide-type local anesthetics.~* Subjects with pregnant partners~* Subject with sexual partners of child-bearing potential and not using appropriate contraception~* Subject, or his sexual partner, has a history of Glucose-6-Phosphate Dehydrogenase (G-6-PD) deficiency or use of medications that would increase susceptibility to methemoglobinemia (e.g. anti-malarial agents).

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Double-Blind Active (Type: ACTIVE_COMPARATOR): Double-blind Phase: Subjects will be randomised to PSD502 respectively if the patient meets all the entry criteria.
- Double-Blind Placebo (Type: PLACEBO_COMPARATOR): Double-blind Phase: Subjects will be randomised to Placebo respectively if the patient meets all the entry criteria.
- Open Label Phase (Type: ACTIVE_COMPARATOR): Subjects will all receive PSD502 if they wish to continue in the trial.

Based on this trial design, predict the completion outcome and termination type (if applicable).